Mission Pharmacal Company, a privately held pharmaceutical company based in San Antonio, has begun exclusive promotion of Elestrin (estradiol gel) 0.06 per cent in the United States through an agreement with Meda AB. Elestrin is a prescription medicine approved by the Food and Drug Administration (FDA) for use as a topical hormone replacement gel to treat moderate-to-severe hot flashes due to menopause. Using estrogen-alone may increase your chance of getting cancer of the uterus (womb).
The addition of Elestrin complements and expands Mission Pharmacal's existing line of branded products for women. Established in 1946 in San Antonio, Texas, the company has a long history of service and expansion in the women's health sector. Mission Pharmacal therapies for women include a premier line of prescription prenatal vitamins, an innovative bone health product, anti-infectives, an iron supplement, a urinary analgesic, and now Elestrin.
"Mission Pharmacal's commitment to women's health has never been stronger," says Dan Kibbe, senior vice president, Pharmaceutical Division, Mission Pharmacal. "The addition of Elestrin further enhances our position as one of the most valuable partners in providing healthcare solutions for obstetricians and gynaecologists (OB/GYNs) and their patients in the women's healthcare community."
Elestrin also directly supports Mission's vision to offer innovative, science-based products that meet the nutritional and healthcare needs of people at every life stage.
"The value we bring to physicians' offices continues to grow with our expanded offerings in women's health," says Brian Card, executive director of Women's Health and Urology Sales, Mission Pharmacal. "Our experienced women's health sales force is able to help general practitioners and OB/GYNs address a full range of everyday clinical situations."
Elestrin provides women with an option to treat moderate-to-severe hot flashes due to menopause with a low dose of estrogen in a topical format. Do not use estrogen-alone to prevent heart disease, heart attacks, strokes, or dementia (decline in brain function). The safety and effectiveness of Elestrin was demonstrated in clinical trials, and it has been available by prescription in the United States since 2006. Women generally enter menopause in their 40s or 50s. The American College of Obstetricians and Gynaecologists (ACOG) reports that the most common symptom of menopause is hot flashes.